GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

ZN-c5   Click here for help

GtoPdb Ligand ID: 13967

Synonyms: compound F [WO2021216671A1] | example 5A [US20210330651A1] | ZNc5
Compound class: Synthetic organic
Comment: ZN-c5 was developed as an orally bioavailable selective estrogen receptor degrader (SERD) [1], for potential to treat breast cancer brain metastases. The core structure of ZN-c5 was used in the design of compounds with improved brain penetration and in vitro and in vivo efficacy, such as compound 5 [PMID: 40393772] [3].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 52.57
Molecular weight 434.48
XLogP 2.72
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@@H]1CC2=C([C@@H](C3=C(C=C(/C=C/C(=O)O)C=C3F)F)N1C45CC(C4)C5)NC6=C2C=CC=C6
Isomeric SMILES C[C@@H]1CC2=C([C@H](N1C34CC(C3)C4)C5=C(C=C(C=C5F)/C=C/C(=O)O)F)NC6=CC=CC=C26
InChI InChI=1S/C26H24F2N2O2/c1-14-8-18-17-4-2-3-5-21(17)29-24(18)25(30(14)26-11-16(12-26)13-26)23-19(27)9-15(10-20(23)28)6-7-22(31)32/h2-7,9-10,14,16,25,29H,8,11-13H2,1H3,(H,31,32)/b7-6+/t14-,16?,25-,26?/m1/s1
InChI Key HGFYTUMJTQXEII-JMAUQWQESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Huang PQ, Hedge SG, Bunker KD, Knight J, Pinchman JR, Unni AK, Sit RK, Zhu S, Hopkins CD, Scott I. (2021)
Preparation of an selective estrogen receptor degrader.
Patent number: WO2021216671A1. Assignee: Recurium Ip Holdings, Llc. Priority date: 21/04/2021. Publication date: 28/10/2021.
2. Huang PQ, Slee DH, Hedge SG, Hopkins CD, Bunker KD, Pinchman JR, Sit RK. (2021)
Estrogen receptor modulators.
Patent number: US20210330651A1. Assignee: KALYRA PHARMACEUTICALS, INC.. Priority date: 06/07/2021. Publication date: 28/10/2021.
3. Zhang G, Huang PQ, Bunker KD, Hegde SG, Ma J, Lee CC, Samatar AA, Unni A, Al-Amin M, Kakarla R. (2025)
Discovery of an Orally Bioavailable and Brain Penetrant Selective Estrogen Receptor Degrader.
J Med Chem, 68 (11): 11990-12003. [PMID:40393772]